Pressure Injuries and Amniotic Membrane Biologics: An Evidence-Based Protocol

# Pressure Injuries and Amniotic Membrane Biologics: An Evidence-Based Protocol

Stage III, Stage IV, and deep tissue pressure injuries persist despite guideline-based care.

The 2019 NPIAP/EPUAP/PPPIA guideline acknowledges advanced biologic adjuncts have a role in Stage III/IV injuries failing optimal standard care (Evidence Level C). Amniotic membrane allografts provide extracellular matrix scaffold, growth factors, and immunomodulatory properties.

Candidacy

Stage III: full-thickness skin loss with visible adipose. Stage IV: extension through full-thickness tissue exposing muscle, tendon, ligament, cartilage, or bone. Biologic candidacy requires: wound duration exceeding 4 weeks; optimal offloading documented; perfusion (ABI ≥0.9, toe pressure ≥40 mmHg, or TcpO₂ ≥30 mmHg); infection controlled; necrotic burden reduced through debridement to granular wound bed.

DTPI is a high-risk precursor. Biologic adjuncts are not indicated for DTPI alone. Aggressive offloading, support surface optimization, and close monitoring. Consider amniotic membrane allografts if DTPI progresses to Stage III or IV.

Unstageable injuries: full-thickness loss with depth obscured by slough or eschar. Debride to establish staging before assessing biologic candidacy.

Wound Bed Preparation: TIME Framework

Necrotic tissue, slough, and biofilm create barrier to graft integration and perpetuate inflammatory cytokine production. Sharp debridement to viable granular base is preferred. Assess bleeding risk and anticoagulation; remove all necrotic tissue, fibrinous slough, and non-viable eschar; debride to granular, bleeding wound bed without undermining; address undermining and tunneling (separate debridement, particulate formats benefit); achieve hemostasis with gentle saline-moistened gauze pressure; avoid electrocautery.

Chronic pressure injuries harbor biofilm in approximately 60 percent. Assume biofilm presence in stalled wounds. Aggressive debridement and wound cleansing before graft placement improve graft take. Avoid cytotoxic agents (povidone-iodine, hydrogen peroxide, Dakin's solution) in immediate pre-graft preparation.

Clinically infected pressure injuries (purulence, advancing erythema, warmth, systemic signs) are not candidates until infection controlled. Obtain wound culture if clinical signs present; initiate systemic antibiotics when indicated; use topical antimicrobial dressings (silver, iodine-impregnated, medical-grade honey) as adjunct; confirm infection resolution; document status and rationale for delaying graft.

Chronic pressure injuries exhibit prolonged inflammatory states. Amniotic membrane allografts demonstrate immunomodulatory properties.

Excessive exudate or desiccation compromises graft adherence. Wound bed moist but not macerated at graft application. Heavy exudate — manage with absorbent primary dressing for 1-2 changes before graft. Minimal exudate — maintain moist environment with hydrocolloid or thin foam. Desiccated beds — hydrate with sterile saline immediately before placement.

Non-advancing or rolled edges indicate stalled epithelial migration. Lightly debride rolled edges.

Offloading

Offloading is the single most critical intervention. NPIAP guidelines classify offloading as Level A evidence.

Support surface selection: Stage I and II — high-specification foam or higher-level surface. Stage III and IV — high-level support surface required.

Repositioning: minimum every 2 hours for standard mattresses; every 3-4 hours for high-level support surfaces. Document repositioning schedule adherence.

CMS documentation: specify support surface type and date of initiation; repositioning schedule and compliance; specific offloading devices; patient education. Failure to document offloading is a common reimbursement denial cause.

Graft Selection

Sheet Grafts

Indications: superficial to moderate depth Stage III injuries without undermining or tunneling; minimal to moderate exudate; uniform wound geometry; areas where contour conformability not critical (sacrum, trochanters).

Advantages: complete wound coverage; preserves ECM architecture and growth factor distribution; ease of application; cost-effective for smaller surface areas.

Limitations: not conform to irregular contours or deep pockets; limited exudate drainage unless fenestrated; require multiple sheets for large surface areas.

Micronized/Particulate Grafts

Indications: deep Stage III/IV injuries with undermining or tunneling; irregular geometry or deep pockets; heavily exudative wounds; pressure injuries over bony prominences with contour irregularities.

Advantages: conforms to irregular geometry and tunnels; be packed into deep spaces; allows exudate drainage without fenestration; be combined with sheet grafts for layered coverage.

Limitations: higher cost per surface area; requires application technique specific to particulate format; be more difficult to contain within wound boundaries.

Reimbursement: CMS reimbursement calculated based on wound surface area, not graft area. Efficient graft sizing and minimizing overlap onto intact skin maximizes cost-effectiveness.

Application Protocol

Pre-application assessment: confirm Stage III or IV pressure injury (unstageable wounds debrided to establish staging); offloading optimized and documented; infection controlled or absent; wound bed debrided to granular base; exudate level manageable; perfusion adequate (ABI ≥0.9, toe pressure ≥40 mmHg, or TcpO₂ ≥30 mmHg); nutritional status optimized (albumin ≥3.0 g/dL, prealbumin trending upward).

Sheet graft application: obtain consent; calculate wound surface area using digital planimetry or ellipse formula; select graft size (cover wound surface with 1-2 mm overlap onto intact periwound skin); rehydrate dehydrated sheet in sterile saline for 2-3 minutes. Transfer sheet using sterile atraumatic forceps; position sheet to cover entire wound surface, ensuring contact with wound margins; smooth sheet gently with saline-moistened cotton-tipped applicator to eliminate air pockets; for irregular contours, gently press sheet into contours; do not suture or staple — fixation achieved through secondary dressing. For heavy exudate, create 3-5 small slits (2-3 mm each) in rehydrated sheet with sterile scalpel; apply fenestrated sheet; ensure slits do not compromise complete coverage.

Particulate graft application: calculate wound volume or surface area for dosing; select particulate format quantity. Apply particulate directly to wound bed using sterile applicator or syringe; for deep tunnels or undermining, gently pack particulate into spaces; ensure complete coverage without overpacking; avoid placing particulate onto intact peri-wound skin.

Secondary dressing: apply non-adherent mesh or silicone contact layer directly over graft, extending 1 cm beyond wound margins onto intact skin. Exudate-based secondary dressing: minimal exudate — hydrocolloid or thin foam; moderate exudate — silicone-bordered foam; heavy exudate — calcium alginate or hydrofiber beneath foam. Secure with tape, transparent film, or tubular netting per anatomic location. Avoid excessive tension at wound edges. Initial dressing change at 48-72 hours. Subsequent changes determined by exudate saturation and wound assessment.

Documentation, Reapplication, Safety

CMS LCDs require comprehensive documentation. Pre-application: pressure injury stage with supporting assessment; wound duration; previous treatments with outcomes; offloading measures; vascular assessment; nutritional assessment; infection status and treatment; rationale for biologic adjunct. Application: product name, lot number, and size; wound surface area calculated; date and time; applying clinician credentials; wound bed preparation; offloading confirmed; pre-application photograph if permitted. Follow-up: wound measurements; percentage surface area reduction; graft adherence; granulation tissue; dressing frequency and tolerance; adverse events; plan for subsequent applications.

Common denial reasons: insufficient offloading documentation; inadequate wound bed preparation documentation; unclear medical necessity; lack of infection control documentation; missing vascular assessment.

Consider reapplication when: wound demonstrates measurable but incomplete healing (20-50% surface area reduction); graft partially adherent with remaining non-granulated areas; new necrotic tissue or slough develop despite initial graft integration; wound exhibits recurrence of biofilm or stalled granulation after initial improvement. Reassess wound bed and repeat TIME framework assessment; debride to granular base if necrotic tissue or slough accumulated; confirm offloading remains optimal; assess for new barriers (infection, vascular changes, nutritional decline); document rationale and expected benefit.

Amniotic membrane allografts are classified as HCT/Ps under 21 CFR 1271, regulated as Section 361 HCT/Ps. Adverse events are generally infrequent and mild: local erythema or irritation (≤5%); graft displacement requiring replacement; mild transient pain; contact dermatitis attributed to processing residuals (rare).

Contraindications: known hypersensitivity to amniotic membrane components or processing agents; active clinical infection (controlled); untreated osteomyelitis; active malignancy in wound bed.

Precautions: patients with significant autoimmune disease require additional monitoring; processing method (cryopreserved vs dehydrated) considered in patients with known processing agent sensitivities.

Summary

Amniotic membrane allografts represent an evidence-informed adjunct for Stage III and IV pressure injuries failing to progress despite optimal standard care. Candidacy requires: Stage III/IV injury present 4+ weeks; optimized offloading (documented support surface and repositioning); adequate perfusion; controlled infection; prepared wound bed (granular base after debridement with TIME framework); adequate nutrition (albumin ≥3.0 g/dL or active optimization).

When criteria are met, amniotic membrane allografts provide extracellular matrix scaffold, growth factors, and immunomodulatory properties that may shift stalled pressure injuries toward healing. Integration with standard care — particularly offloading, moisture management, and multidisciplinary coordination — remains essential.

All procedures should be performed in accordance with manufacturer's Instructions for Use and institutional protocols. Individual outcomes vary; treatment decisions should reflect patient-specific factors, comorbidities, and clinical judgment.

References

1. National Pressure Injury Advisory Panel (NPIAP), European Pressure Ulcer Advisory Panel (EPUAP), and Pan Pacific Pressure Injury Alliance (PPPIA). Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. 2019.

2. Wound Healing Society. Wound Healing Society Guidelines for the Prevention and Treatment of Pressure Ulcers. Wound Repair and Regeneration. 2021.

3. CMS. Local Coverage Determination (LCD) for Skin Substitute Grafts. Medicare Administrative Contractor coverage policy.

4. Manufacturer Instructions for Use for amniotic membrane allograft products. Refer to specific product IFU for application technique and handling.

5. Clinical evidence for amniotic membrane in pressure injuries is emerging. Clinicians should consult peer-reviewed literature indexed in PubMed for current evidence syntheses.

Disclaimer

This protocol is provided for educational purposes only. It does not constitute medical advice or a substitute for clinical judgment. All procedures should be performed in accordance with the manufacturer's Instructions for Use, institutional protocols, and applicable regulations. Reimbursement policies vary by payer, region, and facility type. Verify current CPT/HCPCS codes and coverage with your local Medicare contractor. Individual outcomes vary; treatment decisions should follow manufacturer IFU and institutional protocols.